<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60221">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01683435</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 11-134</org_study_id>
    <nct_id>NCT01683435</nct_id>
  </id_info>
  <brief_title>The Value of HBA in the Evaluation of Idiopathic Infertility</brief_title>
  <official_title>The Value of Hyaluronic Binding Assays (HBA) in the Evaluation of Idiopathic Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We would like to determine if HBAÂ® testing of sperm in couples with presumed idiopathic
      infertility will reveal lower binding percentages than in couples with an identifiable cause
      of infertility either male factor or tubal factor We would like to determine if patients
      with abnormal HBA binding have decreased IVF outcome: decreases clinical pregnancy rate,
      implantation rate, and increased miscarriage rate
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>In each of these groups we will assess presence of HBA bound sperm</measure>
    <time_frame>immediate at time of preforming HBA test</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>hylauronin binding assay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HBA binding assay</intervention_name>
    <description>HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.</description>
    <arm_group_label>hylauronin binding assay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  . All groups will include females under 40 years of age undergoing 1st IVF cycle 3
             groups

               1. Abnormal Semen Analysis (sperm count &lt;10 million/ml and /or rapid progressive
                  motility &lt; 50 %, WHO morphology &lt;30%)  normal HSG , normal ovarian reserve
                  testing and ovulation testing

               2. Unexplained infertility- normal ovarian reserve testing and ovulation testing
                  (FSH&lt; 10, AMH&gt;1.0) Normal ovulatory cycles, normal WHO semen analysis. Normal
                  tubes on HSG or Laparoscopy

               3. Tubal infertility as assessed by HSG or laparoscopy

        Exclusion Criteria:

          -  women over 40, prior failed IVF
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Continuum Reproductive Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>May-Tal Sauerbrun</last_name>
      <phone>508-212-9076</phone>
      <email>msauerbrun@chpnet.org</email>
    </contact>
    <contact_backup>
      <last_name>Martin keltz</last_name>
      <phone>212 523 7751</phone>
      <email>mdkeltz@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Keltz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
